NVO
NYSE · Healthcare
Novo Nordisk A/S
$38.58
+0.62 (+1.63%)
NVO News28 articles
Novo Nordisk Shares Dip Despite FDA Nod for Higher-Dose Wegovy
Novo Nordisk shares declined in Copenhagen trading even after U.S. regulators cleared a higher-dose version of its Wegovy obesity treatment. Competitive pressures from Eli Lilly and looming generic competition in India weighed on investor sentiment.
Eli Lilly's Retatrutide Hits Phase 3 Goals, Stock Pressured by Pricing Concerns
Eli Lilly announced its experimental drug retatrutide achieved primary goals in a Phase 3 trial, significantly reducing blood sugar and weight. The stock declined 1.3% to $918.05 amid an HSBC downgrade and ongoing concerns over drug pricing in the U.S. market.
Hims & Hers Stock Stabilizes as Novo Deal Shifts Focus to Profitability
Hims & Hers Health shares traded near $23.82 Friday, stabilizing after a week of volatility driven by its new branded obesity drug agreement with Novo Nordisk. The shift from compounded medications raises margin concerns despite reducing regulatory risk.
Hims & Hers Stock Extends Rally on Novo Nordisk Patent Settlement
Shares of Hims & Hers Health continued their ascent following a resolution to a patent conflict with Novo Nordisk, which will reintroduce branded GLP-1 medications to its service. Analysts have upgraded the stock but caution about potential margin pressures.
Pfizer Shares Dip Amid Vaccine Policy Clarity, Eczema Drug Progress
Pfizer shares declined slightly as regulatory scrutiny of mRNA vaccines eased, offset by positive mid-stage trial results for its experimental eczema drug tilrekimig.
Hims & Hers Soars on Novo Nordisk Partnership, Analyst Targets Rise
Shares of Hims & Hers Health skyrocketed approximately 49% over two sessions following a new distribution agreement with Novo Nordisk. The deal resolves a legal dispute and will bring branded GLP-1 drugs to the telehealth platform, leading several analysts to raise their price targets.
AbbVie's Early Obesity Drug Trial Shows Promising Weight Loss Results
AbbVie reported its amylin-based obesity candidate ABBV-295 led to significant weight reduction in an early study, with no serious safety issues observed. The data marks a strategic step for the company as it seeks growth beyond immunology.
Hims & Hers Shares Jump on Novo Nordisk Partnership Revival
Hims & Hers Health shares surged in premarket trading Monday following reports that Novo Nordisk will resume selling its weight-loss drugs through the telehealth platform. The move marks a reversal from a patent dispute last month.
Zealand Pharma Stock Crashes on Obesity Drug Data Lagging Lilly
Zealand Pharma A/S shares plunged over 32% Friday after mid-stage trial results for its obesity drug candidate petrelintide showed weight loss well behind Eli Lilly's competing therapy, erasing billions in market value.
FDA Issues Second Ozempic Ad Warning to Novo Nordisk in Escalating Scrutiny
The FDA has sent Novo Nordisk a second advertising violation notice in under a month, citing misleading claims for Ozempic. The agency simultaneously warned 30 telehealth companies about compounded GLP-1 drug promotions.
Lilly Shares Dip Amid Sector Weakness, Focus on Obesity Drug Pipeline
Eli Lilly shares declined 2.3% to $1,028.07 on Monday, underperforming the broader market. The focus remains on the company's obesity drug pipeline and an upcoming FDA review for its oral GLP-1 candidate, orforglipron.
Lilly Shares Slip Amid China Drug Approval, Focus on Obesity Pipeline
Eli Lilly shares declined 2.3% to $1,028.07 Monday despite broader market gains. The dip came as Innovent Biologics secured Chinese regulatory clearance for the cancer therapy Jaypirca, a drug developed with Lilly.
Lilly's Obesity Pill Data Sparks Stock Rebound, FDA Decision Looms
Eli Lilly shares gained nearly 3% to $1,051.99, ending a three-day decline. The move follows new clinical data for its oral obesity treatment, with a key FDA verdict anticipated next month.
Hims & Hers Faces SEC Probe, Novo Nordisk Lawsuit as Analysts Cut Targets
Hims & Hers Health shares held steady premarket following disclosures of an SEC probe and a patent lawsuit from Novo Nordisk. Analysts at BTIG and Citi downgraded the stock, citing regulatory risks.
Eli Lilly Builds $1.5B Inventory for Obesity Pill Ahead of FDA Decision
Eli Lilly shares edged higher Friday as the company disclosed a $1.5 billion inventory build for its experimental weight-loss pill orforglipron, awaiting an FDA decision this spring.
Lilly Builds $1.5B Obesity Pill Inventory Ahead of Key FDA Decision
Eli Lilly shares gained as the pharmaceutical giant disclosed a $1.5 billion inventory build for its experimental oral obesity treatment ahead of an anticipated FDA decision in April.
Lilly Gains on China IBD Drug Approval, Oral GLP-1 Race Heats Up
Eli Lilly shares advanced nearly 2% after securing Chinese approval for its inflammatory bowel disease drug mirikizumab. Investors also await a key U.S. decision on the company's oral weight-loss pill expected in April.
Pfizer Shares Dip in Premarket Amid SEC Settlement, Partnership News
Pfizer stock edged lower in premarket trading following a $29 million SEC settlement agreement and a new biotech incubator partnership. Investors await key inflation data.
Hims & Hers Shares Stabilize After Novo Nordisk Patent Lawsuit Rattles Weight-Loss Strategy
Hims & Hers stock edged up 0.1% premarket following steep declines after Novo Nordisk filed a patent lawsuit over compounded semaglutide. Investors await court developments, FDA signals, and the company's Feb. 23 earnings.
Hims & Hers Shares Extend Decline Amid Novo Nordisk Patent Lawsuit Over Compounded Weight-Loss Drugs
Hims & Hers Health stock fell another 5.6% as Novo Nordisk filed a patent lawsuit seeking to block compounded versions of Wegovy, tightening regulatory pressure on the online health provider's GLP-1 offerings.
Eli Lilly shares retreat as $2.4B Orna acquisition and China partnership draw scrutiny
Eli Lilly's stock declined 0.9% as investors assessed the company's strategic moves into cell therapy and Chinese drug development. The market is weighing increased pipeline spending against intensifying competition in obesity treatments.
Hims & Hers Shares Plunge 16% After Halting $49 Weight-Loss Pill Amid Novo Nordisk Lawsuit
Hims & Hers Health stock tumbled in after-hours trading following the withdrawal of its compounded semaglutide product and a patent infringement lawsuit from Novo Nordisk. Leerink Partners reduced its price target on the company.
Markets Await Key Data, Fed Comments as Futures Show Muted Moves
U.S. stock futures held near flat Monday, with traders focused on upcoming inflation and jobs reports, Treasury buyback details, and scheduled Federal Reserve speeches.
Novo Nordisk Shares Surge as Hims Abandons Low-Cost Semaglutide Pill
Novo Nordisk stock climbed over 8% after Hims & Hers canceled plans for a $49 compounded weight-loss pill. The move follows FDA warnings against unapproved GLP-1 drug marketing.
Novo Nordisk Rebounds as FDA Vows Crackdown on Wegovy Copycats
Novo Nordisk B shares surged 5.29% after Hims & Hers halted its $49 compounded version of Wegovy, with the FDA pledging action against unauthorized copycats. The stock remains down roughly 20% over five sessions amid pricing uncertainty.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly's stock rose 3.7% after the FDA warned Hims & Hers to halt sales of a non-approved compounded GLP-1 weight-loss pill, signaling a regulatory clampdown that may support pricing for branded obesity drugs.
Novo Nordisk Shares Rebound as Hims Halts Wegovy Copycat After FDA Pressure
Novo Nordisk's Class B shares surged 5.3% after Hims & Hers discontinued its compounded Wegovy pill following U.S. regulatory warnings. The stock had dropped nearly 8% when the copycat launched.
NovoCure Shares Surge on FDA Approval for Pancreatic Cancer Device
NovoCure's stock jumped over 20% premarket after the FDA cleared its Optune Pax device for treating locally advanced pancreatic cancer, marking the first new treatment for this condition in nearly three decades.